Eclipsys pays inducement grants following Premise purchase

Eclipsys will issue a total of 64,832 shares of Eclipsys common stock; and non-qualified options to purchase a total of 270,138 shares of common stock to certain employees of Premise.

The stock options are to be paid out as an employment inducement following the close of its recent acquisition of Premise.

All of the common stock is subject to contractual restrictions on transfer until vested: 25 percent of the total number of shares shall vest Dec. 1, 2009, Dec. 1, 2010, Dec. 1, 2011, and Dec. 1, 2012, in each case contingent upon continued employment, with partial pro-rata vesting for time served if employment is terminated by the employee with good reason, or by Eclipsys without cause.

The stock options have a seven-year term, an exercise price per share equal to the fair market value of Eclipsys common stock on the date of grant, and vest over four years, contingent upon continued employment, with partial pro-rata vesting for time served if employment is terminated by the employee with good reason or by Eclipsys without cause.

Around the web

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services.